ImageneBio, Inc. — Director's Dealing 2021

Dec 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-12-10

Reporting Person: Zhang Xiaoyan Michelle (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-10	Common Stock	M	1000	$2.1462	Acquired	45475	Direct
2021-12-10	Common Stock	S	1000	$14.7599	Disposed	44475	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-10	Stock Option (Right to Buy)	$2.1462	M	1000	Disposed	2028-12-17	Common Stock (1000)	Direct

Footnotes

F1: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.